Patent US5652225A successfully refreshed from Google Patents.
US5652225A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods and products for nucleic acid delivery
Assignee: Steward Research and Specialty Projects Corp
•
Filing: 1996-07-03
•
Granted: 1997-07-29
•
Expires: 2016-07-03
Abstract
Abstract The present invention provides a method for the delivery of a nucleic acid to an arterial cell comprising contacting the cell with a hydrophilic polymer incorporating the nucleic acid. The nucleic acid may be any nucleic acid, including antisense DNA or RNA. The nucleic acid may encode hormones, enzymes, receptors or drugs of interest. The nucleic acid is selected based upon the desired therapeutic outcome. For example, in the treatment of ischemic diseases, one would select a DNA encoding an angiogenic protein. The nucleic acid may be carried by a microdelivery vehicle such as cationic liposomes and adenoviral vectors. DNA encoding different proteins may be used separately or simultaneously.
Inventors
- 👤 Jeffrey M. Isner
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:51
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
185 words
A method for inducing the formation of new blood vessels in a desired target tissue in a human host, comprising contacting an arterial cell in an artery or blood vessel via a balloon catheter coated with a hydrogel polymer admixed with a first DNA encoding an angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor and having an operably linked secretory signal sequence or a first DNA encoding a modified angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor having an operably linked secretory signal sequence, wherein said anglogenic protein induces new blood vessel formation when expressed in said target tissue in an amount effective to induce new blood vessel formation.
Claim 2
Independent Claim
185 words
A method for inducing the formation of new blood vessels in a desired target tissue in a human host, comprising contacting an arterial cell in an artery or blood vessel via a balloon catheter coated with a hydrogel polymer admixed with a first DNA encoding an angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor and having an operably linked secretory signal sequence or a first DNA encoding a modified angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor having an operably linked secretory signal sequence, wherein said anglogenic protein induces new blood vessel formation when expressed in said target tissue in an amount effective to induce new blood vessel formation.
Claim 3
Dependent Claim
14 words
The method of claim 1, wherein the angiogenic protein is vascular endothelial growth factor.
Claim 4
Dependent Claim
31 words
The method of claim 1, wherein the hydrogel polymer is selected from the group consisting of polycarboxylic acids, cellulosic polymers, gelatin, polyvinylpyrrolidone, maleic anhydride polymers, polyamides, polyvinyl alcohols, and polyethylene oxides.
Claim 5
Dependent Claim
14 words
The method of claim 1, wherein the hydrogel polymer is a polyacrylic acid polymer.
Claim 6
Dependent Claim
169 words
The method of claim 1, wherein the hydrogel polymer is admixed with a second DNA encoding an angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor and having an operably linked secretory signal sequence or a second DNA encoding a modified angiogenic protein selected from the group consisting of acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor α and β, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor α, hepatocyte growth factor and insulin like growth factor having an operably linked secretory signal sequence, wherein said angiogenic protein induces new blood vessel formation when expressed in said target tissue in an amount effective to induce new blood vessel formation, and wherein said second DNA is not the same as said first DNA.
Claim 7
Independent Claim
61 words
A method for inducing the formation of new blood vessels in a desired target tissue in a human host, comprising contacting an arterial cell in an artery or blood vessel via a balloon catheter coated with a hydrogel polymer admixed with DNA encoding vascular endothelial growth factor and which is expressed in an amount effective to induce new blood vessel formation.
Claim 8
Independent Claim
61 words
A method for inducing the formation of new blood vessels in a desired target tissue in a human host, comprising contacting an arterial cell in an artery or blood vessel via a balloon catheter coated with a hydrogel polymer admixed with DNA encoding vascular endothelial growth factor and which is expressed in an amount effective to induce new blood vessel formation.
References Cited (Backward Citations)
US5091205A
Cited
US5328470A
Cited
US5304121A
Cited
WO1993000052A1
Cited
WO1993000051A1
Cited
US5252479A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-07-28 | 2001-01-27 | 2001-07-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-07-28 | 2005-01-27 | 2005-07-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-07-28 | 2009-01-27 | 2009-07-29 | $7700.00 | Window Closed / Lapsed |